-World-renowned oncology experts, fighting against colorectal cancer and as the cornerstone of combination immunotherapyCTLA-4The therapy has deep insight and rich clinical experience
Suzhou, China and San Diego, USA, March 8, 2024/PRNewswire/ -- Tianyan Pharmaceutical (“Company” or “Tianzhan”) (NASDAQ: ADAG) is a platform-driven clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics based on original antibodies. The company announced today that Heinz-Josef Lenz, a member of the American College of Physicians (FACP) and M.D., has joined the Tianyan Scientific and Strategic Advisory Board (SAB).
Dr. Lenz is the associate director of clinical research and co-leader of translational science programs at USC Norris Comprehensive Cancer Center (USC Norris Comprehensive Cancer Center) under USC Keck Medicine (Keck Medicine), and is the co-director of the USC Norris Cancer Drug Development Center. At the same time, he is a professor of medicine and preventive medicine at the University of Southern California Keck School of Medicine (Keck School of Medicine of USC) and J Terrence Lanni's cancer research chair at the Department of Oncology Medicine.
Dr. Lenz said, “Microsatellite-stabilized colorectal cancer (MSS CRC) is still one of the cold tumors lacking effective immunotherapy, and I believe anti-CTLA-4 therapy will provide a reliable solution. By achieving CTLA-4 mediated intratumoral Treg depletion, the anti-CTLA-4 safety antibody ADG126 combined with pabolizumab in the treatment of microsatellite-stabilized colorectal cancer showed impressive results and had the potential to significantly improve long-term efficacy. At the same time, due to its excellent safety, this anti-CTLA-4 antibody combined with anti-PD-1 therapy can achieve higher doses and higher frequency of repeated administration, which is expected to significantly improve the long-term survival benefits of patients and meet current serious unmet clinical needs.”
Dr. Lenz and his laboratory have received funding from the US National Cancer Institute and have been working to develop innovative drugs in preclinical models for gastrointestinal cancer. As a transformational clinical researcher and translational scientist, Dr. Lenz pioneered the first prospective randomized phase II trial using gene expression results from FFPE specimens. He also discovered that the primary site of colorectal cancer is an independent predictive and prognostic indicator and is now included in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (NCCN Guidelines). Dr. Lenz accelerated translational and clinical research, and trained and guided clinical researchers through the design and implementation of researcher-initiated clinical studies.
Dr. Lenz received his medical doctorate from Johannes Gutenberg University in Mainz, Germany, and completed his internship, residency, and specialist training at Eberhardt-Karls University in Tübingen, Germany in 1991. He was trained as a special specialist at the University of Vienna (Austria), George Washington University, and Harvard Medical School. Currently, more than 570 peer-reviewed papers have been published, and the number of citations (h-index, h-index) has reached 113.
Dr. Luo Peizhi, Chairman of the Board of Directors, CEO and R&D President of Tianyan Pharmaceutical, said, “We agree with Dr. Lenz that anti-CTLA-4 antibody therapy is an important solution for developing immunotherapy for patients with cold cancer such as microsatellite-stabilized colorectal cancer. As an authoritative expert in colorectal cancer, his deep insight and extensive clinical experience will play an important role in developing SafeBody ADG126 for patients around the world.”
For information on the members of the Tianyan Pharmaceutical Science and Strategy Advisory Committee, please visit:
About Tianyan Pharmaceutical
Tianyan Pharmaceutical (NASDAQ: ADAG) is a platform-driven biopharmaceutical company with a clinical product development stage produced by an independent platform. The company is committed to discovering and developing novel cancer immunotherapy based on original antibodies. Using computational biology and artificial intelligence, with its world-first three-body platform technology (new epitope antibody NeoBody, safe antibody SafeBody and Strong Antibody (PowerBody), Tianyan Pharmaceutical has established a unique and original antibody product line focusing on novel tumor immunotherapy to address unmet clinical needs. Tianyan has reached strategic partnerships with a number of world-renowned partners, and uses its various original cutting-edge technologies to empower partners to develop new drugs.
For more information, please visit: Also pay attention to Tianyan PharmaceuticalWeChat,LinkedInandTwitterOfficial account.
SafeBody It is a registered trademark of Tianyan in the US, China, Australia, Japan, Singapore and the European Union.